Roivant Sciences (ROIV) Treasury Shares (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Treasury Shares came in at $348527.0 in Q1 2025, down 96.93% YoY from $11.4 million in Q1 2024, and down 50.92% on a QoQ basis from $710060.0 in Q4 2024.
Roivant Sciences (ROIV) Treasury Shares (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 5 years of Treasury Shares data on file, last reported at $348527.0 in Q1 2025.
- Quarterly Treasury Shares fell 96.93% year-over-year to $348527.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $348527.0 (down 96.93% YoY) and the FY2025 annual result came in at $348527.0, down 96.93% from the prior year.
- Treasury Shares retreated to $348527.0 in Q1 2025, from $710060.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $52.0 million in Q3 2024 to a low of $348527.0 in Q1 2025.
- A 5-year average of $15.8 million and a median of $17.0 million in 2024 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2024 — Treasury Shares soared 525.51% — and 2025, when it slumped 96.93%.
- Tracing ROIV's Treasury Shares over 5 years: stood at $22.6 million in 2021, then declined by 1.92% to $22.2 million in 2022, then plunged by 90.35% to $2.1 million in 2023, then plunged by 66.8% to $710060.0 in 2024, then slumped by 50.92% to $348527.0 in 2025.
- The last three Treasury Shares figures came in at $348527.0 (Q1 2025), $710060.0 (Q4 2024), and $52.0 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 48.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.19 Mn |
| Jun 30, 2026 | 48.19 Mn |
| Mar 31, 2026 | 48.19 Mn |
| Mar 31, 2026 | 48.19 Mn |
| Mar 31, 2025 | 348,527.00 |
| Mar 31, 2025 | 348,527.00 |
| Dec 31, 2024 | 710,060.00 |
| Dec 31, 2024 | 710,060.00 |
| Sep 30, 2024 | 52.01 Mn |
| Sep 30, 2024 | 52.01 Mn |
| Jun 30, 2024 | 16.98 Mn |
| Jun 30, 2024 | 16.98 Mn |
| Mar 31, 2024 | 11.36 Mn |
| Mar 31, 2024 | 11.36 Mn |
| Dec 31, 2023 | 2.14 Mn |
| Dec 31, 2023 | 2.14 Mn |
| Sep 30, 2023 | 20.07 Mn |
| Sep 30, 2023 | 20.07 Mn |
| Jun 30, 2023 | 21.42 Mn |
| Jun 30, 2023 | 21.42 Mn |